The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34984 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Sophie H A E Derks und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Brain Neoplasms, Kidney Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EMC Fellowship, Daniel den Hoed Foundation, Vereniging Trustfonds Erasmus Universiteit Rotterdam.
Abstract (Originalsprache)
A diagnosis of brain metastasis (BM) significantly affects quality of life in patients with metastatic renal cell cancer (mRCC). Although systemic treatments have shown efficacy in mRCC, active surveillance (AS) is still commonly used in clinical practice. In this single‐center cohort study, we assessed the impact of different initial treatment strategies for metastatic RCC (mRCC) on the development of BM. All consecutive patients diagnosed with mRCC between 2011 and 2022 were included at the Erasmus MC Cancer Institute, the Netherlands, and a subgroup of patients with BM was selected. In total, 381 patients with mRCC (ECM, BM, or both) were identified. Forty‐six patients had BM of whom 39 had metachronous BM (diagnosed ≥1 month after ECM). Twenty‐five (64.1%) of these 39 patients with metachronous BM had received prior systemic treatment for ECM and 14 (35.9%) patients were treatment naive at BM diagnosis. The median BM‐free survival since ECM diagnosis was significantly longer ( p = .02) in previously treated patients (29.0 [IQR 12.6–57.0] months) compared to treatment naive patients (6.8 [IQR 1.0–7.0] months). In conclusion, patients with mRCC who received systemic treatment for ECM prior to BM diagnosis had a longer BM‐free survival as compared to treatment naïve patients. These results emphasize the need for careful evaluation of treatment strategies, and especially AS, for patients with mRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
- Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Neurosurgery, Erasmus MC, Rotterdam, The Netherlands.
ORCID-Profile: Sophie H A E Derks
Förderung
- EMC Fellowship
- Daniel den Hoed Foundation
- Vereniging Trustfonds Erasmus Universiteit Rotterdam
Zitieren
APA
Derks, S. H. A. E., van der Meer, E. L., Joosse, A., de Jonge, M. J. A., Slagter, C., Schouten, J. W., Hoop, E. O., Smits, M., van den Bent, M. J., Jongen, J. L. M., & van der Veldt, A. A. M. (2024). The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.34984
Vancouver
Derks SHAE, van der Meer EL, Joosse A, de Jonge MJA, Slagter C, Schouten JW, et al. The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer. International Journal of Cancer. 2024. doi:10.1002/ijc.34984
BibTeX
@article{Derks2024,
author = {Derks, Sophie H A E and van der Meer, Edgar L and Joosse, Arjen and de Jonge, Maja J A and Slagter, Cleo and Schouten, Joost W and Hoop, Esther Oomen-de and Smits, Marion and van den Bent, Martin J and Jongen, Joost L M and van der Veldt, Astrid A M},
title = {The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34984}
}
EUVIMED